ID

Ian Dixon

Tryptamine Therapeutics Limited | Chief Executive Officer
Dr Dixon is a co-inventor of the patented LEAP Technology owned by Exopharm and is also a co-inventor of other Exopharm technologies. Dr Dixon brings to the Board a technical and entrepreneurial background in founding, building and running technology-based companies, in recognising the potential commercial value of early-stage drug development, and in understanding the challenges involved in drug development

Companies and Roles

Company
Title
Tenure
Since
TYP
TYP
Tryptamine Therapeutics Limited
  • Chief Executive Officer
11yrs, 9mthMay 2013
NYR
NYR
Nyrada Inc
  • Founder
  • Non-Executive Director
4yrs, 5mthSep 2020

Holdings

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
NYR
NYR
Nyrada Inc
18/01/25N/A10,380,6991,200,000N/A
TYP
TYP
Tryptamine Therapeutics Limited
01/05/24N/A11,303,451N/AN/A
EX1
EX1
19/04/24N/A11,303,451N/AN/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
NYR
NYR
Nyrada Inc
12/06/24
Issued
266,666$0.075$19,999Placement
EX1
EX1
01/09/21
Exercise
83,333$0.535$44,583Conversion of securities
EX1
EX1
01/09/21
Buy
83,333$0.535$44,583Conversion of securities
NYR
NYR
Nyrada Inc
29/06/21
Issued
192,308$0.260$50,000Placement
NYR
NYR
Nyrada Inc
18/01/21
Issued
1,800,000$0.400$720,000Director remuneration